Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
cipla pharma
30 tablet
Erlotinib
Keep in cold place
Delivering To:
Overview
Erlocip 150mg Tablet is a prescription-based anticancer medicine. It is used for the treatment of pancreatic cancer and non-small cell lung cancer. This tablet has a salt constituent called 'Erlotinib,' which belongs to the drug class of 'kinase inhibitors. It stops the activity of the abnormal protein that leads to cancerous growth. Take it exactly as prescribed at the fixed time each day for better results.
non-small cell lung cancer (NSCLC) and pancreatic cancer
Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Erlocip 150mg Tablet can also have adverse effects on the body, most of which resolve without the need for medical attention.
Some common side effects include:
Abdominal pain
Bone pain
Breathlessness
Constipation
Cough
Diarrhea
Fatigue
Fever
Infection
Muscle pain
Nausea
Rash
Stomatitis (Inflammation of the mouth)
Vomiting
Weight loss
Seek medical attention in case of any unusual or severe side effects immediately.
The doctor determines the dosage and treatment duration with Erlocip 150mg Tablet as per the patient's health condition and stage of cancer. This tablet should be taken orally without food. Don't chew or crush the tablet. In the case of overdose, contact your doctor immediately.
Alcohol
unsafe
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking the Erlocip 150mg Tablet. It is advised to consult your doctor for further information.
Pregnancy
consult your doctor
Erlocip 150mg Tablet may be considered unsafe during pregnancy. Please consult your doctor in such a condition.
Breast Feeding
consult your doctor
Erlocip 150mg Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor.
Driving
danger
It is advisable not to drive or operate heavy machinery after taking an Erlocip 150mg Tablet, as you may feel dizzy.
Kidney
caution
Erlocip 150mg Tablet is safe for use in kidney disease if prescribed by the doctor. No dosage adjustment is necessary for this Tablet.
Liver
caution
Inform your doctor before starting the Erlocip 150mg Tablet if you have liver disease to avoid any serious side effects.
If the patient misses a dose of medicine, skip it and continue with the normal schedule. No need to double the dose
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
1. Bonomi, P. (2003). Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert opinion on investigational drugs, 12(8), 1395-1401.
2. Kelley, R. K., & Ko, A. H. (2008). Erlotinib in the treatment of advanced pancreatic cancer. Biologics: targets and therapy, 2(1), 83-95.
3. Kelley, R. K., & Ko, A. H. (2008). Erlotinib in the treatment of advanced pancreatic cancer. Biologics: targets and therapy, 2(1), 83-95.
4. Liu, V., White, D. A., Zakowski, M. F., Travis, W., Kris, M. G., Ginsberg, M. S., ... & Azzoli, C. G. (2007). Pulmonary toxicity associated with erlotinib. Chest, 132(3), 1042-1044.
5. Scagliotti, G. V., Krzakowski, M., Szczesna, A., Strausz, J., Makhson, A., Reck, M., ... & Govindan, R. (2012). Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non–small-cell lung cancer: a phase III trial. Journal of clinical oncology, 30(17), 2070-2078.
cipla pharma
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.